Size: | Price | Quantity | |
---|---|---|---|
5 mg | $65.00 | ||
25 mg | $215.00 |
RO-3306 (872573-93-8) is a selective inhibitor of CDK1 (IC50 = 35 nM versus CDK2 IC50 = 340nM).1,2 It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4 It has also been demonstrated to overcome apoptotic resistance in BRAFV600E human colorectal cancer cells.5
References/Citations:
1) Vassilev et al. (2006), Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1; Proc. Nat. Acad. Sci. USA 103 10660
2) Krasinska et al. (2008), Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle; Cell Cycle 7 1702
3) Pierce et al. (2013), Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines; Cancer Biol. Ther. 14 537
4) Xia et al. (2014), The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition; Int. J. Oncol. 44 735
5) Zhang et al. (2018), Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer; Mol. Cancer Res. 16 378
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
RO-3306 (872573-93-8) is a selective inhibitor of CDK1 (IC50 = 35 nM versus CDK2 IC50 = 340nM).1,2 It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4 It has also been demonstrated to overcome apoptotic resistance in BRAFV600E human colorectal cancer cells.5
References/Citations:
1) Vassilev et al. (2006), Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1; Proc. Nat. Acad. Sci. USA 103 10660
2) Krasinska et al. (2008), Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle; Cell Cycle 7 1702
3) Pierce et al. (2013), Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines; Cancer Biol. Ther. 14 537
4) Xia et al. (2014), The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition; Int. J. Oncol. 44 735
5) Zhang et al. (2018), Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer; Mol. Cancer Res. 16 378
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.